Business Wire

Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

Del

Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS® (ranibizumab) and SOLIRIS® (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing HERCEPTIN® 3 (trastuzumab).

Under the agreement, C-Bridge will establish a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis across a number of areas, including clinical development, regulatory registration and commercialization in China. Samsung Bioepis will receive an upfront payment, as well as royalties on sales. Additional financial details were not disclosed.

“We want to play an important role in widening access to high-quality healthcare for patients throughout China. C-Bridge is the right partner for this mission as evidenced in its exceptional track record of successfully turning portfolio companies like AffaMed Therapeutics into leading biopharmaceutical companies in China and beyond,” said Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”

Established in February 2012, Samsung Bioepis currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab) and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). In the United States, the company has one biosimilar – RENFLEXIS® (infliximab-abda) –.on the market, while another biosimilar – ONTRUZANT® (trastuzumab-dttb) – has been approved by the U.S. Food and Drug Administration (FDA). A Biologics License Application (BLA) for SB5 (adalimumab) biosimilar candidate is currently under review at the FDA.

In total, over 100,000 patients across the world are currently under treatment with Samsung Bioepis’ biosimilars, with over 6 million doses administered.

About AffaMed Therapeutics

AffaMed Therapeutics is a biopharmaceutical company focused on identifying and licensing late stage candidates for commercialization in emerging Asia Pacific markets and globally. AffaMed was founded and funded by C-Bridge Capital in 2019.

About C-Bridge Capital

C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities across healthcare industry. C-Bridge Capital’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnosis and healthcare services. As of today, the AUM of C-Bridge Capital has exceeded US$1.8 Billion. C-Bridge Capital is committed to support commercialization of cutting-edge technologies and companies that fulfil unmet medical needs, thus continuously improving the standard and quality of care for patients.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

____________________________________________

1 LUCENTIS ® is a registered trademark of Genentech

2 SOLIRIS ® is a registered trademark of Alexion

3 HERCEPTIN ® is a registered trademark of Genentech

Contact information

MEDIA:
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Reply Recognised for its LEA Reply™ Solution in Gartner Market Guide for Yard Management19.2.2019 09:30:00Pressemelding

Reply, with its Supply Chain and Industry 4.0 platform LEA Reply™, has been included in Gartner’s January 2019 Market Guide for Yard Management. LEA Reply™ is an interconnected platform based on a microservices architecture that enables agile and cost-effective supply chain solutions tailor-made for business needs. According to Gartner’s research, “As transportation costs and capacity issues increase, yard management presents opportunities to improve operational efficiency through increased visibility and process optimization.” The Yard Management Solution, incorporated in LEA Reply™, specialises in the management and performance of all activities that typically take place in a yard enabling end-to-end management, offering 100% visibility and control for critical situations, expediting inbound and outbound warehouse processes and allowing the prioritisation of urgent consignments or production line requirements. The Gartner research continues, “Companies are looking into YMS solutions

New Enforce Tac Exhibitor Meggitt Training Systems to Exhibit Portable, Small-Arms Simulator19.2.2019 09:00:00Pressemelding

Meggitt Training Systems will conduct demonstrations of its FATS® 100P portable simulator during its first visit to Enforce Tac (stand 12-129) on March 6-7, 2019, in Nuremberg, Germany. Leveraging key features from the US Army Engagement Skills Trainer II and US Marine Corps Indoor Simulated Marksmanship Trainer programs of record, the industry-leading FATS 100P delivers a significant expansion in virtual small-arms training capability and is ideally suited for use by European law enforcement departments. “As tactical law enforcement challenges evolve, Meggitt is leveraging in-house expertise and customer feedback to expand its line of simulators from the immersive FATS 300 and 180 to the portable 100P,” said Matt Cunningham, Meggitt’s director of virtual systems sales. “Enforce Tac visitors to our stand can learn more, especially how the FATS 100P facilitates training resource sharing among units, as well as enables field deployment for easy set-up in a room that’s not a dedicated tra

ABB Wins $42 Million Order for Train Technologies from Indian Railways19.2.2019 08:30:00Pressemelding

ABB has won its largest traction equipment order in India, worth more than $42 million to supply state-of-the-art converters for electric locomotives from Diesel Locomotive Works (DLW), in Varanasi. The converters are custom designed for Indian Railways and will be manufactured at one of ABB’s largest factories for locomotive applications in Nelamangala, near Bengaluru, in Southern India. ABB’s traction solution is based on the latest technology to bring more reliable trains to passengers, while increasing sustainable transport use by moving from diesel trains to electric. This helps rail operators to achieve significant operational improvements. “We are delighted to be contributing to the electrification of India’s rail network with ABB’s locally manufactured solutions,” said ABB CEO Ulrich Spiesshofer. “By adopting advanced technologies, India is achieving rapid improvements in growth and productivity and shaping its economy for the era of digitalization.” “We are privileged to work

Exclusive Group Further Advances Global VAD Reach with Acquisition of SecureWave in Israel19.2.2019 08:06:00Pressemelding

Exclusive Group, the value-added services and technologies (VAST) group, today announced it is acquiring SecureWave, one of Israel’s leading independent cybersecurity VADs. The move adds another advanced economy to the worldwide market penetration of the Exclusive Group, establishes an in-country presence within one of the world’s most significant innovation hubs, and expands the Group’s service reach to the benefit of its global customers and partners. “This acquisition is about more than just filling in the gaps of our EMEA footprint – it represents a fantastic opportunity to tap into a significant new local market and use our in-country presence to extend relationships with Israeli-based technology innovators,” said Olivier Breittmayer, CEO at Exclusive Group. “In SecureWave we feel we have identified a like-minded VAD business with a committed and successful team who understand value. And as well as similar business principles, we also share some of the same cybersecurity and cloud

The O-RAN Alliance Announces New Open Fronthaul Specification, Demos and Industry Event at Mobile World Congress 201919.2.2019 08:00:00Pressemelding

The O-RAN Alliance announced today that it will be releasing the first O-RAN standard Open Fronthaul Specifications comprised of control, user, synchronization and management plane protocols. Sachin Katti, Stanford University Professor and O-RAN TSC co-chair said, “we are excited to release the first O-RAN Open Fronthaul Specification. O-RAN has leveraged significant specification work done in xRAN and will accelerate interoperability testing and product commercialization. Further, the O-RAN fronthaul workgroup has also started discussions on potential new study items to pursue for 2019.” An O-RAN industry event will kick off the MWC activities on Monday February 25th at 6:00pm, hosted by Deutsche Telekom on its stage in Hall 3. Following this event, O-RAN Alliance members will showcase six strategic proof-of-concepts across various member booths covering four key themes: intelligent RAN control, Open Interfaces, virtualization and white box. Chih-Lin I, China Mobile Chief Scientist an

Gain Therapeutics SA Announces Closing of EU 2.5 Million Series A Financing to Develop Novel Brain-Penetrant Non-Competitive Pharmacological Chaperones for Rare Lysosomal Storage Diseases and CNS Indications19.2.2019 07:30:00Pressemelding

GT Gain Therapeutics SA today announces that it has closed a €2.5 Million series A financing with VitaTech S.A. (€1.1Mio), Helsinn Investment Fund S.A. (€1Mio), and with existing investor TiVenture S.A. (€0.4). Gain Therapeutics SA is a private company, based in Lugano (Switzerland) and with a branch in Barcelona, that exclusively licensed an advanced computational technology (Site-directed Enzyme Enhancement Therapy, SEE-Tx®) used to identify next generation brain-penetrant non-competitive pharmacological chaperones. SEE-Tx® applicable to all diseases with a known genetic mutation in target proteins, allows the identification of brain-penetrant small molecules that provide a gain-of-function of misfolded proteins. Gain Therapeutics has already identified molecules for the treatment of a group of metabolic disorders called lysosomal storage disorders and some chronic degenerative diseases of the nervous system. Prof. Xavier Barril (CSO) commented: “The closing of this first part of ser